Trifarotene (Aklief)
First RAR-gamma selective retinoid for face and trunk acne with innovative efficacy-tolerability balance
About This Treatment
Trifarotene is a fourth-generation retinoid highly selective for the gamma (γ) subtype of nuclear retinoic acid receptor (RAR) and FDA-approved for face and trunk acne treatment (2019). Unlike conventional retinoids (tretinoin, adapalene, tazarotene) showing pan-RAR activity (α/β/γ), trifarotene is RAR-γ specific, minimizing skin irritation accompanying RAR-α activation. Consequently, it maintains high anti-acne efficacy while significantly reducing irritant side effects like erythema, desquamation, and burning sensation. With indication for both face and trunk acne, it represents a new standard in acne treatment.
Mechanism of Action
Trifarotene binds with high selectivity to RAR-γ and activates RAR-γ gene transcription control. In acne pathophysiology, sebum overproduction, follicular keratinization abnormality, Propionibacterium acnes proliferation, and inflammation are involved. RAR-γ activation yields: ①improvement in follicular epithelial keratinization abnormality, ②sebum production suppression via sebaceous gland atrophy, ③suppression of meibomian gland hormones, ④improved follicular structure via remodeling gene expression. Meanwhile, RAR-α activation (primary RAR subtype involved in skin irritation) is minimized, substantially reducing conventional retinoid side effects (irritant dermatitis). High selectivity enables higher concentration use, improving anti-acne efficacy.
Indications
Expected Results
Inflammatory rash markedly decreases within 4-6 weeks; existing lesions improve >50% by 8-12 weeks. New lesion appearance significantly suppressed. Particularly, low irritant side effects enable better tolerability and treatment adherence.
Clinical Evidence
Risks & Side Effects
Initial worsening (initial flare) reported in ~10-20%. Erythema and desquamation seen in early stages but markedly reduced compared to conventional retinoids. Phototoxicity is low (lower than tretinoin) but sun protection recommended. Use contraindicated in pregnancy (Category C).
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition